31-GEP Assay May Help to Extend Survival in Cutaneous Melanoma
Source: Cancer Network, August 2023
Using the 31-gene expression profile assay may help lead to more personalized treatment strategies in patients with cutaneous melanoma, according to Aaron Farberg, MD.
A 3-year follow-up study assessing the impact of the DecisionDx-Melanoma 31-gene expression profile (31-GEP) assay on survival in patients with cutaneous melanoma turned up “remarkable findings,” according to Aaron Farberg, MD.
In an interview with CancerNetwork®, Farberg, a double board-certified dermatologist and fellowship-trained Mohs surgeon who specializes in skin cancer, inflammatory diseases, and cosmetic dermatology, spoke to the significance of the study’s findings, how the 31-GEP assay is being used in clinical practice, and the excitement of waiting for the 5-year and 10-year follow-up data.